Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Synthetic composition and method for treating irritable bowel syndrome

一种组合物、症状的技术，应用在治疗肠易激综合症领域，能够解决生活质量社会成本高、治疗不能令人满意、高发病率等问题

Inactive Publication Date: 2017-08-18
GLYCOM AS
View PDF19 Cites 7 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, most treatments are unsatisfactory and most patients continue to experience chronic pain, fatigue and other symptoms
Although IBS has no direct impact on life expectancy, its high incidence and significant impact on quality of life make it a condition with high social costs

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0070] Embodiment 1-human experiment

[0071] A total of 60 male and female IBS patients were recruited to participate in the study. After a screening visit and a run-in period of 1-2 weeks, patients are selected. The patients were randomly divided into 3 groups, 20 cases in each group, two groups used therapeutic products, and one group used placebo products for 8 weeks. The treatment products contained 5 or 10 grams of the combination of 2'-FL, LNnT, LNT, 3-FL, 6'-SL and 3'-SL, while the control product contained 2 grams of glucose. Both of these products come in powder form in unit-dose containers.

[0072]Eligible patients were: at least 18 years of age, met Rome III criteria for IBS, and had been diagnosed with bacterial overgrowth / dysbiosis. All recruited patients were able and willing to understand and follow study procedures. Patients were excluded if: the patient participated in a clinical study one month prior to the screening visit; they had abnormal results o...

Embodiment 2

[0084] Embodiment 2-human experiment

[0085] A total of 300 male and female IBS patients were recruited to participate in the study. After a screening visit and a run-in period of 1-2 weeks, patients are selected. The patients were randomly divided into two groups, 150 cases in each group, one group used the treatment product, and the other group used the placebo product for 8 weeks. The treatment product contained 5 grams of the combination of 2'-FL and LNnT, while the control product contained 2 grams of glucose. Both of these products come in powder form in unit-dose containers.

[0086] Eligible patients were: between the ages of 18 and 60; met the Rome III criteria for IBS; reported a weekly mean maximum daily abdominal pain intensity score of ≥3 (on a scale of 0-10); Report the frequency of pain / discomfort at least 2 days per week during the period; for IBS-C subgroup patients, report no more than 3 CSBMs per week; for IBS-D subtype patients, report weekly At leas...

Embodiment 3

[0105] Example 3 - Nutritional composition

[0106] The ready-to-eat nutritional composition consists of water, maltodextrin, corn syrup, sugar, milk protein concentrate, vegetable oils (canola, high oleic sunflower, and corn), soy protein isolate, gum arabic, flavoring, HMO, potassium citrate, Magnesium Phosphate, Cellulose Gels and Gums, Calcium Carbonate, Sodium Ascorbate, Soy Lecithin, Choline Bitartrate, Calcium Phosphate, Alpha-Tocopheryl Acetate, Ascorbic Acid, Carrageenan, Iron Pyrophosphate, Flavouring, Sweet Flavor (Stevia), Vitamin A Palmitate, Niacinamide, Vitamin D3, Calcium Pantothenate, Manganese Sulfate, Copper Sulfate, Pyridoxine Hydrochloride, Thiamine Hydrochloride, Beta Carotene, Riboflavin, Chromium Chloride , folic acid, biotin, potassium iodide, phytol hormone, sodium selenite (sodium selinite), sodium molybdate, vitamin B12 preparation.

[0107] The composition provides a nutritional supplement that is a good source of protein, low fat, vitamins, min...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The application relates to synthetic compositions containing one or more human milk mono- or oligosaccharides for use treating irritable bowel syndrome and symptoms relating to irritable bowel syndrome. The HMS is preferably selected from sialic acid and fucose and the HMO is preferably selected from 2'-fucosyllactose (2'-FL), 3-fucosyllactose (3-FL), difucosyllactose (DFL), 3'-sialyllactose (3'-SL), 6'-sialyllactose (6'-SL), lacto-N-tetraose (LNT), lacto-N-neotetraose (LNnT), lacto-N-fucopentaose (LNFP-I) and 3',6-disialyllacto-N- tetraose (DSLNT).

Description

technical field [0001] The present invention generally relates to compositions and methods for treating irritable bowel syndrome (IBS). Background technique [0002] Irritable bowel syndrome is a clinically heterogeneous disorder in humans, especially adults, with chronic symptoms such as abdominal pain, abdominal discomfort, bloating, fatigue and altered bowel motility patterns such as infrequent or more frequent bowel movement patterns, diarrhea and constipation. Routine clinical examination of patients usually shows no abnormalities, although their bowels may be more sensitive to certain stimuli, such as balloon insufflation testing. The worldwide prevalence of IBS is about 10-20% (Longstreth et al., Gastroenterology 130, 1480 (2006)), but may be higher in some countries. The etiology of IBS is unknown, but brain-gut axis disturbance, acute gastrointestinal infection, small intestinal bacterial overgrowth, use of antibiotics, and dysbiosis are considered important risk ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/702A61K31/7004A61K31/7012A61P1/04
CPCA61K31/7004A61K31/7012A61P1/04A61K31/702A61K2300/00A23L33/21A23C9/206A23V2002/00
Inventor T·亨内特B·麦康奈尔E·萨洛蒙松L·K·比格斯奈斯
Owner GLYCOM AS
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com